Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

NCT05430009 is registered in ClinicalTrials.gov with VA Ann Arbor Healthcare System as lead sponsor.

NCT NCT05430009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05430009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
Lead sponsor
VA Ann Arbor Healthcare System
Phase
Phase 1
Overall status
Unknown status
Start date
June 17, 2022
Completion date
June 15, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastases, non-small cell lung cancer